

ARTICLE

Received 29 Oct 2012 | Accepted 30 Apr 2013 | Published 4 Jun 2013

DOI: 10.1038/ncomms2952

# Stac3 is a component of the excitation–contraction coupling machinery and mutated in Native American myopathy

Eric J. Horstick<sup>1,\*</sup>, Jeremy W. Linsley<sup>2,\*</sup>, James J. Dowling<sup>3,\*</sup>, Michael A. Hauser<sup>4</sup>, Kristin K. McDonald<sup>4</sup>, Allison Ashley-Koch<sup>4</sup>, Louis Saint-Amant<sup>1,5</sup>, Akhila Satish<sup>1</sup>, Wilson W. Cui<sup>2</sup>, Weibin Zhou<sup>1,6</sup>, Shawn M. Sprague<sup>1</sup>, Demetra S. Stamm<sup>7</sup>, Cynthia M. Powell<sup>8</sup>, Marcy C. Speer<sup>9</sup>, Clara Franzini-Armstrong<sup>10</sup>, Hiromi Hirata<sup>11</sup> & John Y. Kuwada<sup>1,2</sup>

Excitation–contraction coupling, the process that regulates contractions by skeletal muscles, transduces changes in membrane voltage by activating release of  $\text{Ca}^{2+}$  from internal stores to initiate muscle contraction. Defects in excitation–contraction coupling are associated with muscle diseases. Here we identify *Stac3* as a novel component of the excitation–contraction coupling machinery. Using a zebrafish genetic screen, we generate a locomotor mutation that is mapped to *stac3*. We provide electrophysiological,  $\text{Ca}^{2+}$  imaging, immunocytochemical and biochemical evidence that *Stac3* participates in excitation–contraction coupling in muscles. Furthermore, we reveal that a mutation in human *STAC3* is the genetic basis of the debilitating Native American myopathy (NAM). Analysis of NAM *stac3* in zebrafish shows that the NAM mutation decreases excitation–contraction coupling. These findings enhance our understanding of both excitation–contraction coupling and the pathology of myopathies.

<sup>1</sup>Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, Michigan 48109, USA. <sup>2</sup>Cell and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan 48109, USA. <sup>3</sup>Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA. <sup>4</sup>Departments of Medicine and Ophthalmology, Duke University Medical Center, Durham, North Carolina 27710, USA. <sup>5</sup>Departement de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, Québec, Canada H3T 1J4. <sup>6</sup>Department of Pediatrics and Communicative Diseases, University of Michigan, Ann Arbor, Michigan 48109, USA. <sup>7</sup>Department of Internal Medicine, University of California, Davis, Sacramento, California 95817, USA. <sup>8</sup>Departments of Pediatrics and Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. <sup>9</sup>Center for Human Genetics, Duke University, Durham, North Carolina 27710, USA. <sup>10</sup>Department of Cell and Developmental Biology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. <sup>11</sup>Center for Frontier Research, National Institute of Genetics, Mishima 411-8540, Japan. \* These authors contributed equally to this work. Correspondence and requests for materials should be addressed to H.H. (email: hihirata@nig.ac.jp) or to J.Y.K. (email: kuwada@umich.edu).

Muscle contractions are initiated by depolarization of the voltage across the plasma membrane resulting from synaptic release at the neuromuscular junction (NMJ). Excitation–contraction (EC) coupling is responsible for transducing the shift in the membrane voltage to increase cytosolic levels of  $\text{Ca}^{2+}$  that leads to contraction. Genetic defects in EC coupling components are associated with numerous congenital myopathies<sup>1</sup> that appear in infancy and are characterized by a variety of symptoms that include muscle weakness, difficulty with breathing and feeding, slower development, muscle cramps, stiffness and spasm, and in some cases susceptibility to malignant hyperthermia, which is an adverse reaction to general anaesthesia that can be fatal. Despite the debilitating nature of congenital myopathies, their pathology is for the most part poorly understood. Congenital myopathies are highly heterogeneous, and the genetic basis of many disorders are unknown.

In skeletal muscles, EC coupling occurs at triads. Triads are junctions of the transverse tubules that are infoldings of the sarcomere and the sarcoplasmic reticulum (SR), an internal  $\text{Ca}^{2+}$  store. Changes in the membrane voltage of the transverse tubules are detected by the dihydropyridine receptor (DHPR), an L-type  $\text{Ca}^{2+}$  channel located in the transverse tubule membrane at triads<sup>2–5</sup>. DHPR is composed of the principal  $\alpha_1$ s subunit also called  $\text{Ca}_v1.1$  that contains the pore and several accessory subunits. Activated DHPR, in turn, is thought to directly activate ryanodine receptor 1 (RyR1)  $\text{Ca}^{2+}$  release channels in the SR membrane side of the triadic junctions<sup>6–9</sup>. In mammalian skeletal muscles, the DHPR also conducts extracellular  $\text{Ca}^{2+}$  to the cytosol but this is not required for EC coupling<sup>10</sup>. Interestingly, in teleost skeletal muscles EC coupling is similarly independent of  $\text{Ca}^{2+}$  influx from the exterior and the DHPR appears to have evolved so that it no longer conducts  $\text{Ca}^{2+}$  (ref. 11). Activation of RyR1 leads to release of  $\text{Ca}^{2+}$  from the SR to the cytosol and subsequently to contraction mediated by the contractile machinery.

EC coupling involves a complex of proteins localized to triads that include DHPR and RyR1. Although DHPR and RyR1 are well studied, the identity and roles of other components of the complex, how EC coupling is regulated and how the triadic molecular complex is established are poorly understood. Some of the other components of the triadic complex include FKBP12, triadin, junctin and calsequestrin. Triadin, junctin and calsequestrin are SR proteins that regulate RyR1 from the luminal side of SR<sup>12–14</sup>. FKBP12 is an immunophilin, an immunosuppressive drug-binding protein, that copurifies and co-immunoprecipitates with RyR1 in striated muscles<sup>15</sup>, and stabilize RyRs in their open state *in vitro*<sup>16</sup>. Two other cytosolic proteins that interact with EC


components are SepN1 and calmodulin (CaM). SepN1 is a selenoprotein that co-immunoprecipitates with RyR1a and is associated with myopathy<sup>17</sup> and is required for formation of slow twitch muscles in zebrafish<sup>18</sup>. CaM can bind RyR and DHPR, and modify EC coupling<sup>19</sup>. Despite the identification of these factors, the mechanisms for how they regulate EC coupling is poorly understood. These analyses illustrate the complexity of the EC coupling complex and its regulation, and suggest that a forward genetic strategy might be useful for identification of novel components for EC coupling.

Zebrafish have been useful for the analysis of a myriad of biological processes both because they are amenable to forward genetic screens and *in vivo* manipulations<sup>20,21</sup>. Pertinent to a genetic analysis of EC coupling, zebrafish muscles can also be analysed *in vivo* with electrophysiology and live imaging<sup>22,23</sup>. We took advantage of these features to identify a zebrafish mutation in which EC coupling was defective. The gene responsible for the mutant phenotype encoded for Stac3, a putative muscle-specific adaptor protein. Finally, we found that a missense mutation in human *STAC3* is responsible for the debilitating, congenital Native American myopathy (NAM)<sup>24,25</sup>.

## Results

**The *mi34* zebrafish mutant is defective in EC coupling.** To identify new genes involved in the regulation of EC coupling, a forward genetic screen in the zebrafish was performed to isolate motor behaviour mutants<sup>26–30</sup>. One mutation, *mi34*, was autosomal recessive with mutants dying as larvae and exhibiting defective motor behaviours at early stages of development. Normally zebrafish embryos exhibited spontaneous slow coiling of the body starting at 17 h post fertilization (hpf), touch-induced escape contractions of the body at 22 hpf and touch-induced swimming by 28 hpf (ref. 31). Mutants were defective in all three motor behaviours with reduced amplitude of spontaneous coiling, decreased touch-induced escape contractions and ineffective swimming (Supplementary Movies S1–6; Fig. 1a).

Aberrant behaviour in mutants could be due to defects in the nervous system and/or skeletal muscles. If signalling within the nervous system were abnormal in mutants, then one would expect the output of motor neurons to muscles to be aberrant. To determine this, the synaptic response of muscles to tactile stimulation of the embryo was electrophysiologically recorded *in vivo*. Tactile stimulation initiated synaptic responses in both slow and fast twitch muscles in both wild-type (wt) sibling and mutant embryos. The evoked responses were comparable in amplitude, duration and frequency, when measured with a low



**Figure 1 | *mi34* mutant zebrafish exhibit defective swimming but CNS output is normal.** (a) Touch evoked swimming in wt but not *stac3<sup>mi34</sup>* embryos (48 hpf). Panels show superimposed frames (30 Hz) of swimming motion from wt sibling and *stac3<sup>mi34</sup>* embryos with heads embedded in agar. (b) Voltage recordings with 6-mM curare showing that touch-evoked synaptic responses of slow twitch (wt sib:  $n = 5$ ; mut:  $n = 6$ ) and fast twitch muscles (wt sib:  $n = 6$ ; mut:  $n = 4$ ) of wt sibling and *stac3<sup>mi34</sup>* mutants (48 hpf) are comparable. (c) Voltage recordings with no curare showing that mutant fast twitch muscles (48 hpf) respond to tactile stimulation with a burst of action potentials ( $n = 8$ ).


concentration of curare (see Methods) used to minimize muscle contraction (Fig. 1b; Supplementary Fig. S1). To see if the mutant muscles would generate action potentials in response to synaptic input, we examine muscle responses following sensory stimulation without curare, which was possible because contraction by mutant muscles is minimal. These recordings showed that mutant fast twitch muscles do respond with a burst of overshooting action potentials (Fig. 1c). Furthermore, there were no obvious differences in the distribution of motor neuron terminals and muscle acetylcholine receptors (AChRs) between wt sibs and mutants when assayed with an antibody against SV2, a synaptic vesicle protein, and  $\alpha$ -bungarotoxin that specifically binds AChRs (Supplementary Fig. S2). Thus, the nervous system and NMJ between wt and mutants is comparable and mutant muscles can initiate bursts of action potentials in response to synaptic input. Although we cannot rule out subtle changes, the severity of the behavioural phenotype is consistent with the mutation causing a defect in the muscle response to electrophysiological activation.

Activation of the NMJ leads to depolarization of the muscle membrane potential that in turn initiates muscle contraction. To examine how the mutation affects the relationship between muscle voltage and contraction, the membrane voltage of skeletal muscles was depolarized to various values and the amount muscles contracted was measured. Mutant muscles contracted much less than wt sib muscles at depolarized membrane potentials (Supplementary Fig. S3). The decreased contraction to depolarizations could be due to a defect in EC coupling or a defect in the contractile machinery. However, the fact that mutant and wt sib muscles contracted similarly when exposed to caffeine, an agonist of RyRs, (Supplementary Fig. S4) suggested that the contractile machinery was intact in mutants and that the store of  $Ca^{2+}$  in the SR was not grossly perturbed. Corroborating this finding, mutant muscles exhibited no obvious morphological


defects early in the development with apparent normal distribution of contractile proteins and other muscle proteins (Supplementary Fig. S4). Furthermore, myofibers appeared normal in electron micrographs of larval skeletal muscles in *mi34* mutants (Fig. 2a). These findings pointed to a defect in EC coupling in mutant muscles.

The hallmark of EC coupling is the release of  $Ca^{2+}$  from the SR to the cytosol. EC coupling was directly examined *in vivo* by imaging  $Ca^{2+}$  transients in skeletal myofibers, expressing the GCaMP3  $Ca^{2+}$  indicator<sup>32</sup> during swimming. Swimming was evoked by application of NMDA, which activated the swimming network in the central nervous system<sup>28</sup>.  $Ca^{2+}$  transients were greatly reduced in both mutant slow and fast twitch fibres (Fig. 2b,c). Thus, EC coupling in skeletal muscles was defective in the *mi34* mutants. As EC coupling takes place at triads, reduced EC coupling in mutants could be due to abnormal formation of triads. However, longitudinal sections examined with transmission electron microscopy showed that there were triads at every intermyofibrillar junction with triads exhibiting comparable anatomy including two rows of feet in wt sib and mutant muscles (Fig. 2a). Although we cannot rule out a quantitative change in triadic anatomy, these data showed that the decrease in EC coupling in mutant muscles was not due to any obvious defect in triad anatomy.

***stac3* is the basis for the *mi34* phenotype.** A combination of meiotic mapping and analysis of zebrafish genome resources identified the gene responsible for the *mi34* phenotype as *stac3* (Supplementary Fig. S5; for details see Methods), a gene similar to murine *stac* that encodes an adaptor-like protein of unknown function<sup>33</sup>. *stac3* encodes for a putative 334 residue soluble protein with an N-terminal cysteine-rich domain (CRD) similar



**Figure 2 | EC coupling is defective in *mi34* mutant zebrafish embryos.** Electron micrographs showing that the ultrastructure of myofibrils and triadic junctions are comparable between the muscles of 4 days post fertilization (dpf) wt sibling (a, left) and *mi34* mutants (a, right). Top: longitudinal sections showing several myofibrils and triads sectioned at right angle to the T tubule long axis. Scale: 500 nm. Bottom: at left a section tangent to the triad, showing one of the two long rows of feet (RyR) that occupy the junctional gap. Scale: 250 nm. Bottom: at right a section transverse to the triad axis showing two feet (arrowheads) in the junctional gap of the triad. Scale: 100 nm. (b)  $Ca^{2+}$  transients recorded from GCaMP3-expressing fast and slow twitch fibres are significantly decreased and slower in 48 hpf *stac3*<sup>mi34</sup> mutants. (c) Left: quantification of peak  $Ca^{2+}$  release with black and grey bars representing wt sib (fast,  $n=5$ ; slow,  $n=5$ ) and *stac3*<sup>mi34</sup> (fast,  $n=9$ ; slow,  $n=7$ ) fibres, respectively. #Denotes that peak  $Ca^{2+}$  was 0. Right: quantification of  $Ca^{2+}$  transient kinetics in fast fibres with black and grey bars representing wt sib and *stac3*<sup>mi34</sup>, respectively. Half width denotes the duration the transient is  $>50\%$  of peak value. Error bars represent s.e.m.'s. Asterisks signifies  $P < 0.01$ , t-test.




**Figure 3 | The muscle-specific gene *stac3* underlies the *mi34* phenotype.** (a) Diagram of the predicted wt Stac3 protein (top). Arrow denotes location of the stop codon. DNA sequence of corresponding regions of wt cDNA, wt genomic DNA and *stac3*<sup>mi34</sup> cDNA showing that a missense mutation in a splice donor site lead to the inclusion of the intron (bracket) and stop codon (asterisk) in the mutant cDNA. (b) Stac3 protein appears not to be synthesized in mutants. Western blot of showing that anti-Stac3 labels a band from wt but not mutant embryos at 48 hpf. β-Actin was the loading control. (c) Stac3 co-localizes with RyR and DHPR<sub>α1</sub> in the skeletal muscles. Left, side view of the trunk of 48 hpf embryos labelled with anti-Stac3 showing that both fast twitch and slow twitch express Stac3 in wt but not mutant embryos. Scale: 60 μm. Inset shows the brightfield image of the trunk of the mutant. Right, dissociated 48 hpf wt muscle fibres labelled with anti-Stac3 and anti-RyR or anti-DHPR<sub>α1</sub> showing that Stac3 co-localizes with RyR and DHPR<sub>α1</sub>. Scale: 10 μm.

to the C1 domain found in Ca-dependent protein kinase and two SH3 domains (Fig. 3a). The mutant allele carried a point mutation that disrupted a splice donor site that led to the inclusion of intron 4 and a premature stop codon in the transcript. The mutation in *stac3* predicted a protein that was truncated within the N-terminal CRD, suggesting that the *stac3*<sup>mi34</sup> mutation was functionally null. Western blotting with an antibody generated against Stac3 that recognized a fragment of Stac3 consisting of the residues 1–63 (see Methods) revealed an ~49 kDa protein in wt embryos but no protein in mutants (Fig. 3b), suggesting that a truncated protein was not synthesized in mutants. *In situ* hybridization showed that skeletal muscles selectively expressed *stac3* during embryogenesis (Supplementary Fig. S6). Labelling with anti-Stac3 confirmed that Stac3 was specifically expressed by skeletal muscles and revealed that Stac3 co-localized with the DHPR<sub>α1</sub> and presumably RyR1 at muscle triads in wt but was not expressed in mutant embryos (Fig. 3c). These findings suggested that a mutation in *stac3* was responsible for defective EC coupling and that Stac3 was a component of the triadic molecular complex.


The molecular identity of the mutation was confirmed by mutant rescue experiments. Induced expression of *hsp70:stac3*<sup>wt-egfp</sup> in mutant muscles rescued the behavioural phenotype and triadic localization of Stac3, whereas induced expression of *hsp70:stac3*<sup>mi34-egfp</sup> did not (Fig. 4a). Furthermore, Ca<sup>2+</sup> imaging of mutant muscles coexpressing *stac3*<sup>wt-mCherry</sup> and *GCaMP3* showed that wt Stac3 could restore Ca<sup>2+</sup> muscle transients in mutant embryos (Fig. 4b,c). Given that Stac3 may be an adaptor protein and co-localizes with DHPR<sub>α1</sub> and RyR1, we examined whether Stac3 may be part of the triadic molecular complex. Indeed co-immunoprecipitations with antibodies against pan-RyR and DHPR<sub>α1</sub> both pulled down Stac3 from wt adult muscles (Fig. 5), indicating that Stac3 is part of the DHPR/RyR1

complex found at triads. This was confirmed by generating a transgenic line of zebrafish (*α-actin:stac3*<sup>wt-egfp</sup>) that expressed Stac3-EGFP in the skeletal muscles and by using anti-GFP to immunoprecipitate Stac3-EGFP from lysates of skeletal muscle of adult transgenic zebrafish. Mass spectrometry-based protein identification found that DHPR<sub>α1s</sub>, DHPR<sub>α2δ1</sub>, DHPR<sub>β1</sub>, RyR1 and RyR3 immunoprecipitated with Stac3-EGFP (Supplementary Table S1). Thus, Stac3 is a component of the triadic complex that is required for EC coupling in skeletal muscles.

Although motor behaviours are greatly diminished in *stac3*<sup>mi34</sup> mutants, they were not immotile. One possible reason for this might be the existence and action of Stac3 derived from maternally deposited *stac3* mRNA. In fact, RT-PCR (PCR with reverse transcription) from 2hpf embryos (before zygotic expression<sup>34</sup>) found that *stac3* was maternally expressed (Fig. 6a). To see whether the residual activity of skeletal muscles in *stac3*<sup>mi34</sup> mutants was due to Stac3 translated from maternal mRNA, we knocked down Stac3 by injecting a translation-blocking antisense Morpholino oligonucleotide (MO) against *stac3* message into embryos from crosses between heterozygous carriers. Anti-Stac3 labelling showed that *stac3* antisense MO-injected embryos did not express Stac3 in the skeletal muscles (Fig. 6b), confirming that the MO was effective. At 48 hpf wt embryos normally respond to tactile stimulation by swimming away. As expected from a cross between heterozygous carriers ~75% of the progeny injected with control MO responded to touch with swimming whereas 25% responded by slight muscle contractions (shivering) that failed to move the embryos effectively or were totally immotile (Fig. 6c), indicative of the mutant phenotype. In antisense MO-injected embryos, however, there was a significant increase in embryos that were either immotile or shivered and decrease in embryos that swam compared with control progeny. Significantly the proportion of



**Figure 4 | Expression of wt *Stac3* in muscles rescues the *stac3<sup>mi34</sup>* phenotype.** (a) Left, histogram showing that mutant embryos expressing heat-inducible *stac3<sup>wt</sup>-egfp* (black,  $n = 32$ ) but not *stac3<sup>mi34</sup>-egfp* (light grey,  $n = 4$ ) nor uninjected mutant embryos (dark grey,  $n = 10$ ) exhibited touch-evoked swimming at both 3 h post heat shock (hphs) and 24 hphs. #Denotes no swimming. Right panels, superimposed frames (30 Hz, 1 s) (top) show that mutant embryos expressing *stac3<sup>wt</sup>* but not *stac3<sup>mi34</sup>* swim in response to touch, although both are similarly expressed by muscles (middle, scale: 180  $\mu$ m). In dissociated mutant muscles *Stac3<sup>wt</sup>-EGFP* localizes to the triads but not *Stac3<sup>mi34</sup>-EGFP* (bottom, scale: 10  $\mu$ m). (b) *In vivo* expression of *Stac3<sup>wt</sup>-mCherry* by mutant muscle fibres rescues  $Ca^{2+}$  transients. Left panels, *stac3<sup>mi34</sup>* mutant slow and fast twitch fibres coexpressing  $\alpha$ -actin-driven GCaMP3 and heat-induced *Stac3<sup>wt</sup>-mCherry*. The triadic localization of *Stac3<sup>wt</sup>-mCherry* cannot be seen due to the low resolution of the resonance scans used to detect the fluorescent proteins. (c) Top,  $Ca^{2+}$  transients from mutant fast and slow fibres coexpressing *Stac3<sup>wt</sup>-mCherry* and GCaMP3. Middle, histogram showing that peak  $Ca^{2+}$  release is comparable between wt (black) fast ( $n = 5$ ) and slow ( $n = 5$ ) fibres, and rescued mutant (grey) fast ( $n = 6$ ) and slow ( $n = 2$ ) fibres. Bottom, histogram showing that the kinetics of  $Ca^{2+}$  transients from wt (black) and rescued mutant (grey) fast twitch fibres are comparable. Error bars represent s.e.m.'s.




**Figure 5 | *Stac3* forms a molecular complex with DHPR and RyR.** (a) Immunoblots (IB) showing that immunoprecipitation (IP) with anti-DHPR $\alpha$ 1 but not mouse IgG pulls down DHPR $\alpha$ 1 and *Stac3* from adult skeletal muscle lysate ( $n = 3$ ). Skeletal muscle lysate lane is an immunoblot showing *Stac3* and DHPR $\alpha$ 1 are expressed by muscles. (b) Immunoblots showing that immunoprecipitation with anti-pan-RyR but not mouse IgG pulls down RyR and *Stac3* from adult skeletal muscle lysate ( $n = 3$ ). Skeletal muscle lysate lane is an immunoblot, showing *Stac3* and RyR are expressed by the muscles.

coinjecting an expression plasmid for *stac3<sup>wt</sup>* along with the antisense MO, demonstrating that the increased defective motility observed was not due to an off-target effect of the antisense MO, but rather a specific knockdown of maternal *stac3*. This suggests that elimination of both maternal and zygotic *Stac3* results in immotility.

**A mutation in human *STAC3* causes a congenital myopathy.**

The loss of *Stac3* resulted in a progressive breakdown of myofibers during larval stages with apparent swollen SR observed by 7 days post fertilization (Supplementary Fig. S7). Given the myopathic features of mutants, we explored whether *stac3* mutations might cause congenital human myopathies. Human *STAC3* mapped to chromosome 12q13-14, and its specific location was within the previously defined genetic locus for the congenital NAM (refs 24,25). NAM is an autosomal recessive disorder found within the Lumbee Native American population of North Carolina that was characterized by a constellation of clinical features, including congenital onset of muscle weakness, susceptibility to malignant hyperthermia, multiple joint contractures and dysmorphic facial features including ptosis. Patient muscle biopsies revealed a non-specific myopathic pattern. Furthermore,

immotile embryos increased from ~5% of control MO-injected progeny to almost 40% of antisense MO-injected progeny. Furthermore, the morphant phenotype was rescued by



**Figure 6 | *stac3* mRNA is maternally expressed.** (a) RT-PCR from 2 and 3 hpf embryos showing that *stac3* mRNA is maternally expressed. Midblastula transition starts at 3 hpf. *stac3* mRNA is not expressed in the adult brain. *tuba1*, a house-keeping gene that is maternally expressed, serves as a positive control and *stac3* in the adult brain as a negative control. *stac3* 5' and 3' refer to primers used for amplifying either 5' or 3' fragments of *stac3* from *stac3* cDNA (see Methods). (b) Micrographs showing anti-Stac3 labelled embryos (48 hpf) that had been injected with *stac3* antisense MO (top) but not control MO (bottom) exhibit little to no Stac3. Muscle nuclei are labelled with 4',6-diamidino-2-phenylindole (DAPI; blue). Scale: 5  $\mu$ m. (c) Knocking down Stac3 in 48 hpf embryos significantly increases the proportion of progeny from a cross between *stac3*<sup>mi34</sup> heterozygous carriers that are immotile or shiver and decreases those that swim in response to touch. \*Denotes that the percentage of *stac3* MO-injected progeny that were immotile or shivered was greater than control MO-injected progeny (respectively,  $P < 0.001$  and  $P < 0.01$ ; t-test); percentage of *stac3* MO-injected progeny that swam was less than control MO-injected progeny ( $P < 0.001$ , t-test). \*\*Denotes that coinjection of an expression plasmid for *stac3*<sup>wt</sup> with *stac3* antisense MO decreases immotility and restores swimming in a great majority of progeny. Percentage of *stac3* MO + expression plasmid for *stac3*<sup>wt</sup>-injected progeny that were immotile was much less than *stac3* MO alone progeny ( $P < 0.001$ , t-test). Error bars represent s.e.m.'s.

36% of afflicted individuals die by the age of 18. The genetic basis of NAM remained unsolved, though the presence of susceptibility to malignant hyperthermia as a clinical feature suggested a defect in a component of the EC coupling apparatus. To see whether a mutation in *STAC3* was the basis for NAM, *STAC3*-coding regions were sequenced in a cohort of five NAM families that included 5 affected and 13 unaffected individuals. As expected for an autosomal recessive disorder, all affected individuals were homozygous for a G > C missense mutation of base pair 1,046 in exon 10 of the *STAC3* gene (Ensembl transcript ID ENST00000332782), while all obligate carriers were heterozygous. This mutation resulted in a tryptophan (W) to serine (S) substitution at amino acid 284 in the first SH3 domain (Fig. 7). The sequence change perfectly segregated with the NAM phenotype, and was neither found in an additional three unaffected, unrelated Lumbee individuals (Supplementary Fig. S8), nor in 113 Caucasian control individuals. In addition, *STAC3* has been sequenced as part of the 1,000 genome project, and this mutation has not been detected. This pattern of inheritance suggested that *STAC3* was the basis for the congenital myopathy.


Next the functional consequences of the W284S mutation was investigated in the zebrafish model system. The analogous W > S substitution was encoded in zebrafish *stac3* (*hsp70:stac3*<sup>NAM-egfp</sup>) and expressed in *stac3*<sup>mi34</sup>-null mutant muscles to assay for phenotypic rescue. Unlike *stac3*<sup>wt-egfp</sup>, expression of *stac3*<sup>NAM-egfp</sup> failed to rescue touch-induced swimming, although some *Stac3*<sup>NAM</sup> localized to triads (Fig. 8a). Furthermore, Ca<sup>2+</sup> imaging of mutant fast but not slow twitch muscles expressing *stac3*<sup>NAM-mCherry</sup> and *GCaMP3* exhibited Ca<sup>2+</sup> transients that were decreased compared with mutant muscles expressing *stac3*<sup>wt-mCherry</sup> and *GCaMP3* (Figs 4b and 8b,c). Presumably the mosaic expression of a partially effective allele was insufficient to result in behavioural rescue. Decreased Ca<sup>2+</sup> transients in fast

twitch but not slow twitch muscles expressing *stac3*<sup>NAM</sup> predicts defective swimming, as by 48 hpf swimming is dependent on fast twitch muscle contractions and independent of slow twitch contractions<sup>35</sup>. Additionally, expression of wt human *STAC3* in mutant zebrafish muscles rescued the motor phenotype (Supplementary Fig. S9). Thus, the NAM mutation appeared to diminish EC coupling in fast twitch muscles and was causative for the congenital myopathy.

## Discussion

This study identified Stac3 as a novel component of EC coupling in skeletal muscles, and a mutation in *STAC3* as the cause for NAM. A recent study suggested that MO-mediated knockdown of *stac3* in zebrafish embryos resulted in defective myofibrillar formation in skeletal muscles<sup>36</sup>, but we found that myofibrils in embryonic and larval zebrafish were comparable between *wt* sibs and *stac3* mutants. This discrepancy might be due to the maternal *wt stac3* transcript found in *stac3* nulls, which could have been sufficient for normal myofibrillar formation in mutants.

In principle, Stac3 could participate in EC coupling via a variety of mechanisms. One possibility is that Stac3 might modulate the channel properties of DHPR and/or RyR1. The triadic localization of Stac3 and biochemical demonstration that Stac3 is part of the DHPR/RyR1 complex are consistent with this possibility. Regulation of DHPR or RyR1 channel properties by other triadic components include modulation of the properties of DHPR by RyR1 and of RyR1 by FKBP12. In murine RyR1-deficient myotubes, the complement of DHPR on the muscle membrane is normal, but the DHPRs pass much less Ca<sup>2+</sup> than normal<sup>37</sup>. The immunophilin, FKBP12, copurifies with RyR, and anti-FKBP12 can pull down RyR in striated muscles<sup>14</sup>. When



**Figure 7 | Missense mutation in human *STAC3* causes NAM.** Left top, sequence chromatographs of corresponding exonic region of the *STAC3* gene of individuals that were +/+, +/- and -/- for the NAM locus showing the G>C missense mutation in the *stac3* gene. N denotes the G/C heterozygous nucleotide. Right top, pedigree of an individual exhibiting NAM (black) and homozygous for the missense mutation (C/C). Unaffected parents were carriers for the mutation (G/C) and the unaffected sibling was homozygous for the wt nucleotide (G/G). Middle, alignment of the corresponding region of *Stac3* containing NAM mutation showing that the missense mutation results in a W>S substitution in NAM individuals and that this W is completely conserved between various mammals and zebrafish. Bottom, diagram showing that the missense mutation in *Stac3*<sup>NAM</sup> is located in a SH3 domain.

RyRs were examined with single channel recordings, FKBP12 was found to optimize channel function<sup>15</sup>. The  $\beta$ -subunits of voltage-dependent Ca channels are also known to regulate properties of a variety of Ca channels<sup>38</sup>. It is possible that *Stac3* could interact with the  $\beta_{1a}$ -subunit to regulate DHPR channel properties in the skeletal muscles.

Another possibility is that *Stac3* may regulate the precise organization of DHPRs and RyR1s at triadic junctions of the t-tubules and SR. At triads, DHPRs and RyR1s are organized in a precise manner with DHPRs arranged in geometrically arranged groups of four called tetrads, with each tetrad apposed to every other RyR1 homotetramer<sup>39</sup>. The  $\beta_{1a}$ -subunit of DHPR also appears to be critical for this, as  $\beta_{1a}$  is required for the formation of DHPRs into tetrads<sup>23</sup>.

*Stac3* might also regulate the amount of DHPR and/or RyR1 at triads, perhaps by modulating protein trafficking and/or stability of DHPR and/or RyR1. An example of a factor that may be important for trafficking or stability of DHPRs is REM, a member of the RGK GTP-binding protein family. REM can bind  $\beta$ -subunits of voltage-dependent  $Ca^{2+}$  channels, when expressed heterologously, and overexpression of REM inhibits L-type  $Ca^{2+}$  channels in C2C12 cells<sup>40</sup> and skeletal muscles due to a decrease of DHPR in the muscle membrane<sup>41</sup> via dynamin-dependent

endocytosis<sup>42</sup>. Although the loss-of-function phenotype for REM is not known, these results suggest that REM inhibits localization of DHPRs in triads either by decreasing processing of the channels into triadic junctions or by increasing the removal of the channel from triads. Interestingly the DHPR $\beta_1$  subunit regulates the levels of plasma membrane DHPR $\alpha_{1c}$  ( $Ca_v1.2$ ) that is expressed by cardiac muscle cells and neurons by inhibiting the degradation of these channels via endoplasmic reticulum-associated protein degradation<sup>43</sup>. Examination of the amount of DHPR and RyR1 at triads in *stac3* mutants versus wt muscles should clarify whether *Stac3* controls the levels of these key components in skeletal muscles. Furthermore, it should be possible to investigate whether *Stac3* regulates protein trafficking of key components of EC coupling using various transgenics combined with live-imaging strategies in zebrafish to directly examine fluorescently labelled EC components, as they are trafficked from the ER to triads and are endocytotically removed from the triads. Furthermore, the availability of mutants deficient for DHPR (refs 23,29) and RyR1 (ref. 30), in addition to the *stac3*<sup>mi34</sup> mutant, should be invaluable for mechanistic analysis of *Stac3* for EC coupling.


The NAM mutation converted W284 to S in the first SH3 domain of *Stac3*. Interestingly, an analysis of binding specificities of SH3 domains using a generic structure-based model found that this W, which is in the loop region of the SH3 domain and is highly conserved across SH3 domains, is one of the most important residues for binding specificity<sup>44</sup>. Our finding that expression of *Stac3*<sup>NAM</sup> in *Stac3*-null zebrafish leads to decreased EC coupling suggests that interactions of the first SH3 domain in *Stac3* is important for normal EC coupling. In fact, components of the triadic molecular complex including DHPR $\alpha_{1s}$ , DHPR $\beta_{1a}$  and RyR1 contain numerous SH3-binding sequences in their predicted cytoplasmic portions. Thus, it would be interesting to see whether *Stac3* might interact with triadic components such as DHPR and/or RyR1 via the *Stac3* SH3 domain and whether such an interaction is necessary for normal EC coupling. Interestingly, the structure-based model also identified three other residues found in human *Stac3* (Y255, E283 and N299) that also significantly affected binding specificity<sup>44</sup>. The roles of these residues for EC coupling could be examined by expressing appropriately mutagenized *Stac3* in the zebrafish *stac3* nulls.

Genetic and physiological approaches should also be useful for the generation of transgenic lines of *stac3*<sup>NAM</sup> mutant zebrafish to delineate the pathology of NAM and for identifying potential therapeutic agents. This is particularly relevant, given the increasing recognition of mutations in genes associated with EC coupling in a growing range of human muscle diseases. In addition, *STAC3* is an attractive candidate for the genetic basis of currently undefined congenital myopathies, particularly those associated with susceptibility to malignant hyperthermia and/or those with phenotypes similar to those of patients with *RYR1* or *DHPR* mutations.

## Methods

**Animals and behavioural analysis.** Zebrafish were bred and maintained according to approved guidelines of the University Committee on Use and Care of Animals at the University of Michigan. The *stac3*<sup>mi34</sup> mutation was isolated from a mutagenesis screen using procedures previously reported<sup>19,20</sup>. Embryonic behaviours were video recorded with a CCD camera mounted on a stereomicroscope and analysed with ImageJ. In some cases, the heads of embryos were embedded in low melting temperature agar with the trunk and tail free to move. Where indicated data were analysed by *t*-tests.

**Electrophysiology.** Previously published protocols were followed to electrophysiologically record from zebrafish embryonic muscles<sup>21</sup>. For recordings embryos were partially curarized (6  $\mu$ M d-tubocurarine). Recordings of muscle responses to touch were made with patch electrodes (3–10 M $\Omega$ ) filled with solution containing 105 mM K gluconate, 16 mM KCl, 2 mM MgCl<sub>2</sub>, 10 mM HEPES, 10 mM



**Figure 8 | The *stac3*<sup>NAM</sup> allele decreases EC coupling.** (a) Expression of *Stac3*<sup>NAM</sup> by muscle fibres in *stac3*<sup>mi34</sup> embryos does not rescue touch-evoked swimming. Superimposed frames (30 Hz) showing that a heat-induced mutant embryo previously injected with *pHSP70:stac3*<sup>NAM-egfp</sup> does not swim following tactile stimulation (top), despite expression of zebrafish *Stac3*<sup>NAM</sup>-EGFP in myotomes and triadic localization of zebrafish *Stac3*<sup>NAM</sup>-EGFP (middle, scale bars: 180 and 10  $\mu$ m). Histograms (bottom) quantify the comparable lack of touch-evoked swimming of *stac3*<sup>mi34</sup> mutants expressing the NAM allele (black) and uninjected mutants (grey) both 3 and 24 h post heat shock (hphs). Note the difference in scale of the y axis from that in Fig. 4a that shows swimming in mutant rescued embryos. #Denotes zero movement. (b) Expression of *Stac3*<sup>NAM</sup> by muscle fibres in *stac3*<sup>mi34</sup> embryos partially rescues  $\text{Ca}^{2+}$  transients *in vivo*. Examples of *stac3*<sup>mi34</sup> mutant slow and fast twitch fibres coexpressing  $\alpha$ -actin-driven GCaMP3 and *hsp70*-regulated zebrafish *Stac3*<sup>NAM</sup>-mCherry. The triadic localization of *Stac3*<sup>wt</sup>-mCherry cannot be seen due to the low resolution of the resonance scans used to detect the fluorescent proteins. (c) Top,  $\text{Ca}^{2+}$  transients from mutant fast and slow fibres coexpressing *Stac3*<sup>NAM</sup>-mCherry and GCaMP3. Middle, histogram showing that peak  $\text{Ca}^{2+}$  release is decreased between mutant fast fibres expressing *stac3*<sup>wt</sup> (grey,  $n = 6$ ) and *stac3*<sup>NAM</sup> (white,  $n = 6$ ). Peak  $\text{Ca}^{2+}$  was not different for mutant slow twitch fibres (wt,  $n = 2$ ; NAM allele,  $n = 2$ ). Bottom, histogram showing the kinetics of  $\text{Ca}^{2+}$  transients of mutant fast fibres expressing *stac3*<sup>wt</sup> (grey,  $n = 5$ ) and *stac3*<sup>NAM</sup> (white,  $n = 9$ ). Asterisk signifies  $P < 0.01$ , *t*-test. Error bars represent s.e.m.'s.

EGTA and 4 mM  $\text{Na}_3\text{ATP}$  at 273 mOsm and pH 7.2 and extracellular Evans solution (134 mM NaCl, 2.9 mM KCl, 2.1 mM  $\text{CaCl}_2$ , 1.2 mM  $\text{MgCl}_2$ , 10 mM glucose and 10 mM Hepes at 290 mOsm and pH 7.8) using an Axopatch 200B amplifier (Axon Instruments), low-pass filtered at 5 kHz and sampled at 1 kHz. Mechanosensory stimulation was delivered by ejecting bath solution from a pipette using a Picospritzer. Voltage dependence of contraction was performed in a similar manner except embryos were exposed to 50  $\mu$ M d-tubocurarine, voltage steps delivered to muscle via voltage clamp and muscle contractions video recorded at 60 Hz. Muscle contractions to caffeine applied by a Picospritzer (10 psi, 1 s) of dissected embryos were video recorded and measured.

**$\text{Ca}^{2+}$  imaging.** One-cell stage embryos were injected with a plasmid using  $\alpha$ -actin promoter<sup>29</sup> ( $\alpha$ -actin:*GCaMP3*) resulting in embryos that mosaicly expressed  $\alpha$ -actin:*GCaMP3* within skeletal muscle. Forty-eight hours post fertilization embryos were genotyped by behaviour. Before imaging, tricaine was removed and embryos allowed to recover in Evans for 10 min and treated with 200  $\mu$ M N-benzyl-p-toluene sulphonamide to inhibit contraction for 5 min. Hundred

micromolar NMDA was added to initiate the swimming motor network<sup>17</sup>. GCaMP3-expressing cells were frame scanned at 200 Hz using the resonance scanner of a Leica SP5 confocal microscope. Confocal software was used to measure relative fluorescence intensity changes and kinetics of induced  $\text{Ca}^{2+}$  transients.

**Immunolabelling.** Whole mount embryos were immunolabelled as described previously<sup>26</sup>. For labelling dissociated skeletal muscle fibres, 48 hpf embryos were incubated in collagenase type II (3.125 mg ml<sup>-1</sup> in  $\text{CO}_2$ -independent medium) at 20 °C for 1.5 h with the muscle fibres triturated every 30 min. Fibres were spun at 380 g for 5 min, supernatant removed and fibres resuspended and allowed to settle on polyornithine-coated coverslips. Fibres were washed then fixed. Dissociated muscles were labelled using 0.25% detergent in the incubation solutions containing the following primary antibodies/toxin: 1/200 dilution of anti-RyR (34C IgG1, Sigma); 1/200 anti-DHPR<sub>v1</sub> (1A IgG1, Affinity BioReagents); 1/10 bungarotoxin-Alexa594 (Invitrogen); 1/500 anti-SV2; 1/200 anti- $\alpha$  actinin; and 1/200 anti-dystrophin (all from Iowa Hybridoma Bank). In some cases nuclei were labelled with 0.1% 4',6-diamidino-2-phenylindole.



**Positional cloning of *stac3*.** To identify the gene mutated in *stac3<sup>mi34</sup>* mutants, the mutation was meiotically mapped to PCR-scorable, polymorphic CA repeats as described previously<sup>45</sup> by scoring 2009 mutant embryos derived from appropriate mapping crosses. Flanking markers were identified located on linkage group 9; z1830 that was 0.21 cM north of *stac3<sup>mi34</sup>* and z1663 that was 1.24 cM south. Analysis of the zebrafish genome database (<http://www.sanger.ac.uk/resources/zebrafish/>) revealed that z1830 was located in a small contig of assembled sequence (Scaffold 450) from the zV5 assembly of the sequenced genome that contained the *pchp2* gene. A new marker (zh1) located in *pchp2* mapped 0.11 cM north of *stac3<sup>mi34</sup>*. A sequenced 156-kb BAC (CR848672) that contained *pchp2* was identified and analysed for potential genes with the gene prediction program, GENSCAN (<http://genes.mit.edu/GENSCAN.html>), and BLASTing predicted genes against the NCBI database (<http://www.ncbi.nlm.nih.gov/BLAST>). These were *pchp2*, *kif5a*, *arp5* and a gene similar to *stac*. New markers, zh34 in *kif5a* (0.04 cM north), zh16 in *arp5* (0.04 cM south) and zh31 in the *stac*-like gene (no recombinants), were identified. The *stac*-like cDNA from wt and mutant embryos were isolated and sequenced, and the mutant cDNA contained an insertion that included an in-frame stop codon. Analysis of genomic sequences determined that the *stac3<sup>mi34</sup>* allele contained a missense mutation that transformed a splice donor site for the intron between exons 4 and 5 (GT to AT), which presumably lead to incorrect splicing and inclusion of the intron in the cDNA.

**Mutant rescue.** Rescue of *stac3<sup>mi34</sup>* behaviour was performed by subcloning zebrafish *stac3<sup>wt</sup>*, *stac3<sup>mi34</sup>*, *stac3<sup>NAM</sup>* or human *STAC3* into *pHSP70-EGFP*<sup>42</sup>. Zebrafish *stac3<sup>NAM</sup>* construct was generated by site-directed mutagenesis. Constructs (10 ng  $\mu\text{l}^{-1}$ ) were injected into one-cell stage progeny of *stac3<sup>mi34</sup>* carriers with a Nanoject II. At 48 hpf, *stac3<sup>mi34</sup>* mutant embryos were behaviourally identified and heat induced by switching them from water at 28.5 °C to 37 °C for 1 h. After heat induction, embryos were switched back to 28.5 °C and assayed 3 and 24 h later. Embryos with ~10% or more skeletal muscle fibres expressing EGFP were used for behavioural assays. Responses of embryos to touch were video recorded and measured. For  $\text{Ca}^{2+}$  imaging of *Stac3<sup>wt</sup>*- or *Stac3<sup>NAM</sup>*-expressing muscle fibres *pHSP70:stac3<sup>wt</sup>-mCherry* and *pHSP70:stac3<sup>NAM</sup>-mCherry* were generated along with  $\alpha$ -actin:*GCaMP3*. Embryos were injected with a 1:1 mixture of a *stac3* construct and  $\alpha$ -actin:*GCaMP3* each at 10 ng  $\mu\text{l}^{-1}$ . After heat induction, embryos with skeletal muscle fibres expressing both constructs were selected for  $\text{Ca}^{2+}$  imaging.

**Analysis of maternal transcripts by RT-PCR.** The start of midblastula transition and earliest zygotic transcription is at 3 hpf in zebrafish<sup>34</sup>. Fifty embryos at 2 and 3 hpf each were placed in Trizol, and RT-PCR was performed for *stac3* and *tuba1* (*tubulin  $\alpha$ 1*), a house-keeping gene that is maternally expressed<sup>46</sup>. Exon-overlapping primer pairs shown below were designed to amplify ~200-bp fragments of cDNA from the 5' (representing exons 3–6) or 3' (exons 4–10) region of mature *stac3* message. 5' Primer pair (forward: 5'-GGACGACAACACTGTGTTATTTGTGTATG-3'; reverse: 5'-GAACCCAGGAGGTATTTTGGCCGAAGCA TCT-3'); 3' primer pair (forward: 5'-ACGGATGATTGTTCTCAATAATA AGTTTC-3' reverse: 5'-CGCAACAGATGACAAGAACAAGAAGCAG-3').

**Antisense MO knockdowns.** 4.6 nl of 400  $\mu\text{M}$  solutions of translation-blocking antisense MO (GeneTools) or standard control MO were injected into recently fertilized embryos from crosses of *stac3<sup>mi34</sup>* carriers using a Nanoject II. The sequence of the antisense *stac3* MO was: 5'-TCATATTGAGCCATCAGTCCAGC-3' with CAT corresponding the start ATG. For morphant rescue experiments, 10 ng  $\mu\text{l}^{-1}$  of  $\alpha$ -actin:*stac3-egfp* was coinjected along with the antisense MOs. Embryos were assayed for response to touch with forceps at 48 hpf and subsequently fixed and assayed with anti-*Stac3*.

**Polyclonal antiserum production and purification.** Full-length zebrafish *Stac3* was expressed as a His-Sumo fusion protein in B21(DE3) cells (Invitrogen), and affinity-purified using Ni-NTA agarose. Protein was further purified by electrophoresis in a NuPAGE 4–12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) Bis-Tris Gel and subsequent excision of appropriate Coomassie-stained band. Rabbits were immunized with gel slices of purified fusion proteins. Antiserum was purified by passing through a Sulfolink column (Thermo) containing the immobilized fusion protein. Fragment of *Stac3* that was bound by anti-*Stac3* was identified as follows. Full-length *stac3* cDNA and the fragment that encodes amino acids 1–63 were cloned in frame into pGADT7 (Clontech), which contains an N-terminal HA tag and Gal4 activation domain. Each construct was transformed into Y2HGold Yeast using Yeastmaker Yeast Transformation system 2 (Clontech) and plated on appropriate auxotrophic media. Yeast was grown, collected and protein extracted with YPER yeast protein extraction reagent (Thermo). Protein samples were loaded for SDS-PAGE analysis, blotted onto nitrocellulose and probed separately with anti-HA or anti-*Stac3*.

**Western analysis and immunoprecipitation.** Fifty *stac3<sup>mi34</sup>* mutant and sibling embryos each were collected, lysed and the isolated protein loaded and separated by SDS-PAGE<sup>22</sup>. Anti-DHPR<sub>z1</sub> was used for immunoblotting at 1:500, anti-pan-

RyR at 1:2,000. Adult female fish were killed using 0.1% tricaine, skeletal muscle dissected on dry ice and total protein extracted. Protein lysate from an individual fish was immunoprecipitated using anti-DHPR<sub>z1</sub> (1:100), or anti-pan-RyR (1:200) cross-linked with BS<sup>3</sup> (Thermo) to Protein G Dynabeads (Invitrogen).

**Generation of stable transgenic line.**  $\alpha$ -Actin:*stac3-gfp* construct was injected at 20 ng  $\mu\text{l}^{-1}$  into the cytoplasm of embryos at the one-cell stage. Fish were raised to adulthood and germline founders identified by screening F1 progeny for GFP fluorescence. GFP-positive offspring were raised to establish the transgenic line.

**Mass spectrometry and data analysis.** Skeletal muscle lysates from 10 adult  $\alpha$ -actin:*stac3-gfp* transgenic fish were pooled for immunoprecipitation with anti-GFP (Torrey Pines Biolabs Inc.) or normal mouse IgG. The pull-down fraction was separated using SDS-PAGE, and the fractions in the gel stained using Silver Stain Kit (Pierce). Thirteen bands appearing in the anti-GFP pull-down fraction lane but not in normal IgG pull-down lane were excised, washed with 25 mM ammonium bicarbonate followed by acetonitrile, reduced with 10 mM dithiothreitol at 60 °C followed by alkylation with 50 mM iodoacetamide at room temperature, and digested with trypsin at 37 °C for 4 h. Mass spectrometry was performed by the University of Michigan Proteomics and Peptide Synthesis Core using a nano LC/MS/MS with a Waters NanoAcquity HPLC system interfaced to a ThermoFisher LTQ Orbitrap Velos. Peptides were loaded on a trapping column and eluted over a 75- $\mu\text{m}$  analytical column at 350 nl  $\text{min}^{-1}$ ; both columns were packed with Jupiter Proteo resin (Phenomenex). The mass spectrometer was operated in data-dependent mode, with MS performed in the Orbitrap at 60,000 FWHM resolution and MS/MS performed in the LTQ. The fifteen most abundant ions were selected for MS/MS.

MS/MS samples were analysed using Mascot (Matrix Science, London). Mascot was set up to search the ipi.DANRE.v3.75.decoy database (74,790 entries). Mascot was searched with a fragment ion mass tolerance of 0.50 Da and a parent ion tolerance of 10.0 p.p.m. Carbamidomethyl of cysteine was specified in Mascot as a fixed modification.

Scaffold (version Scaffold\_3.1.2, Proteome Software Inc., Portland, OR) was used to validate MS/MS-based peptide and protein identifications. Peptides were identified at >95% probability and proteins were identified if they contained at least two identified peptides with each peptide identified in the protein at >95% probability. Peptide and protein probabilities were assigned by the Protein Prophet algorithm<sup>47</sup>. Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony.

**Molecular analysis of NAM.** The cohort of individuals with NAM was previously described<sup>34</sup>. NAM subjects were of Lumbee Indian descent with congenital muscle weakness who demonstrate two or more of the following phenotypic characteristics: myopathic facies, susceptibility to malignant hyperthermia, kyphoscoliosis and cleft palate. The probands were ascertained from the University of North Carolina at Chapel Hill Pediatric Genetics Clinic and from the Duke University Muscular Dystrophy Clinic. All data and samples were collected following informed consent of subjects; this study was approved by the Duke University Medical Center and the University of North Carolina Institutional Review Boards. DNA was extracted from whole blood using the Puregene system (Gentra Systems, Minneapolis, MN) and stored in the laboratory of the Duke Center for Human Genetics.

Initially, each exon and the surrounding splicing regions of *STAC3* were screened in three NAM patients and three related individuals through PCR amplification and automated Sanger sequencing. After identification of the NAM mutation in exon 10 of *STAC3*, the entire cohort of available samples from NAM pedigrees was screened by exon amplification and sequencing for the mutation. In all, a total of 18 individuals from five Lumbee families were sequenced, as well as three unrelated unaffected Lumbee individuals. In addition, genomic DNA was screened from two neurologically normal control individuals (Coriell Institute NDPT006 and NDPT009) and from a collection of 111 adult subjects without evidence of neurological disease<sup>48</sup>.

**Electron microscopy.** Transmission electron microscopy was performed as previously described<sup>7,49</sup>. A minimum of three larvae per condition were examined.

## References

1. Sewry, C. A., Jimenez-Mallebrera, C. & Muntoni, F. Congenital myopathies. *Curr. Opin. Neurol.* **5**, 569–575 (2008).
2. Rios, E. & Brum, G. Involvement of dihydropyridine receptors in excitation-contraction coupling in skeletal muscle. *Nature* **325**, 717–720 (1987).
3. Tanabe, T. *et al.* Primary structure of the receptor for calcium channel blockers from skeletal muscle. *Nature* **328**, 313–318 (1987).
4. Adams, B. A., Tanabe, T., Mikami, A., Numa, S. & Beam, K. G. Intramembrane charge movement restored in dysgenic skeletal muscle by injection of dihydropyridine receptor cDNAs. *Nature* **346**, 569–572 (1990).

5. Bannister, R. A. Bridging the myoplasmic gap: recent developments in skeletal muscle excitation-contraction coupling. *J. Muscle Res. Cell Motil.* **28**, 275–283 (2007).
6. Takeshima, H. *et al.* Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. *Nature* **339**, 439–445 (1989).
7. Block, B. A., Imagawa, T., Campbell, K. P. & Franzini-Armstrong, C. Structural evidence for direct interactions between the molecular components of the transverse tubule/sarcoplasmic reticulum junction in skeletal muscle. *J. Cell Biol.* **107**, 2587–2600 (1988).
8. Paolini, C., Fessenden, J. D., Pessah, I. N. & Franzini-Armstrong, C. Evidence for conformational coupling between two calcium channels. *Proc. Natl Acad. Sci.* **101**, 12748–12752 (1994).
9. Lanner, J. T., Georgiou, D. K., Joshi, A. D. & Hamilton, S. L. Ryanodine receptors: structure, expression, molecular details, and function in Ca release. *Cold Spring Harb. Perspect. Biol.* **2**, a003996 (2010).
10. Gonzales-Serratos, R., Valee-Aguilera, R., Lathrop, D. A. & del Carmen Garcia, M. Slow inward calcium currents have no obvious role in muscle excitation-contraction coupling. *Nature* **298**, 292–294 (1982).
11. Schredelseker, J., Shrivastav, M., Dayal, A. & Grabner, M. Non-Ca<sup>2+</sup>-conducting channels in fish skeletal muscle excitation-contraction coupling. *Proc. Natl Acad. Sci.* **107**, 5658–56663 (2010).
12. Beard, N. A., Laver, D. R. & Dulhunty, A. F. Calsequestrin and the calcium release channel of skeletal and cardiac muscle. *Prog. Biophys. Mol. Biol.* **85**, 33–69 (2004).
13. Knollmann, B. C. *et al.* Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca<sup>2+</sup> release, and catecholaminergic polymorphic ventricular tachycardia. *J. Clin. Invest.* **116**, 2510–2520 (2006).
14. Chopra, N. *et al.* Ablation of triadin causes loss of Ca<sup>2+</sup> release units, impaired excitation-contraction coupling, and cardiac arrhythmias. *Proc. Natl Acad. Sci. USA* **106**, 7636–7641 (2009).
15. Jayaraman, T. *et al.* FK506 binding protein associated with the calcium release channel (ryanodine receptor). *J. Biol. Chem.* **268**, 9474–9477 (1992).
16. Brillantes, A. B. *et al.* Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. *Cell* **77**, 513–523 (1994).
17. Moghadaszadeh, B. *et al.* Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. *Nat. Genet.* **29**, 17–18 (2001).
18. Jurynec, M. J. *et al.* Selenoprotein N is required for ryanodine receptor calcium release channel activity in human and zebrafish muscle. *Proc. Natl Acad. Sci. USA* **105**, 12485–12490 (2008).
19. Halling, D. B., Aracena-Parks, P. & Hamilton, S. L. Regulation of voltage-gated Ca<sup>2+</sup> channels by calmodulin. *Sci. STKE* **2006**, er1 (2006).
20. Haffter, P. *et al.* The identification of genes with unique and essential functions in the development of the zebrafish, *Danio rerio*. *Development* **123**, 1–36 (1996).
21. Driever, W. *et al.* A genetic screen for mutations affecting embryogenesis in zebrafish. *Development* **123**, 37–46 (1996).
22. Buss, R. R. & Drapeau, P. Physiological properties of zebrafish embryonic red and white muscle fibers during early development. *J. Neurophysiol.* **84**, 1545–1557 (2000).
23. Schredelseker, J. *et al.* The  $\beta_{1a}$  subunit is essential for the assembly of dihydropyridine receptor arrays in skeletal muscle. *Proc. Natl Acad. Sci. USA* **102**, 17219–17224 (2005).
24. Stamm, D. S. *et al.* Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia. *Am. J. Med. Genet. A* **146A**, 1832–1841 (2008).
25. Stamm, D. S. *et al.* Novel congenital myopathy locus identified in Native American Indians at 12q13.13-14.1. *Neurology* **71**, 1764–1769 (2008).
26. Hirata, H. *et al.* *Accordion*, a zebrafish behavioral mutant, has a muscle relaxation defect due to a mutation in the ATPase calcium pump SERCA1. *Development* **131**, 5457–5468 (2004).
27. Hirata, H. *et al.* Zebrafish *bandoneon* mutants display behavioral defects due to a mutation in the glycine receptor b subunit. *Proc. Natl Acad. Sci. USA* **102**, 8345–8350 (2005).
28. Cui, W. W., Low, S., Hirata, H., Geisler, R., Hume, R. I. & Kuwada, J. Y. The zebrafish *sho* gene encodes a glycine transporter and is essential for the function of early neural circuits in the CNS. *J. Neurosci.* **25**, 6610–6620 (2005).
29. Zhou, W., Shirabe, K., Thisse, C., Thisse, B. & Kuwada, J. Y. Non-sense mutations in the dihydropyridine receptor  $\beta 1$  gene, *CACNB1*, paralyze zebrafish *relaxed* mutants. *Cell Calcium* **39**, 227–236 (2006).
30. Hirata, H. *et al.* Zebrafish *relatively-relaxed* mutants have a ryanodine receptor defect, exhibit slow swimming and provide a model of multi-minicore disease. *Development* **134**, 2771–2781 (2007).
31. Saint-Amant, L. & Drapeau, P. Time course of the development of motor behaviors in the zebrafish embryo. *J. Neurobiol.* **37**, 622–632 (1998).
32. Tian, L. *et al.* Imaging neural activity in worms, flies and mice with improved GCaMP calcium indicators. *Nat. Methods* **6**, 875–881 (2009).
33. Suzuki, H. *et al.* Stac, a novel neuron-specific protein with cysteine-rich and SH3 domains. *Biochem. Biophys. Res. Commun.* **229**, 902–909 (1996).
34. Kane, D. A. & Kimmel, C. B. The zebrafish midblastula transition. *Development* **119**, 447–456 (1993).
35. Nanagawa, Y. & Hirata, H. Developmental transition of touch response from slow muscle-mediated coiling to fast muscle-mediated burst swimming in zebrafish. *Dev. Biol.* **355**, 194–204 (2011).
36. Bower, N. I. *et al.* Stac3 is required for myotube formation and myogenic differentiation in vertebrate skeletal muscle. *J. Biol. Chem.* **287**, 43936–43949 (2012).
37. Nakai, J., Dirksen, R. T., Nguyen, H. T., Pessah, I. N., Beam, K. G. & Allen, P. D. Enhanced dihydropyridine receptor channel activity in the presence of ryanodine receptor. *Nature* **380**, 72–75 (1996).
38. Dolphin, A. C.  $\beta$  Subunits of voltage-gated calcium channels. *J. Bioenerg. Biomem.* **35**, 599–620 (2003).
39. Block, B. A., Imagawa, T., Campbell, K. P. & Franzini-Armstrong, C. Structural evidence for direct interaction between the molecular components of the transverse tubule/sarcoplasmic reticulum junction in skeletal muscle. *J. Cell Biol.* **107**, 2587–2600 (1988).
40. Finlin, B. S., Crump, S. M., Satin, J. & Andres, D. A. Regulation of voltage-gated calcium channel activity by the REM and Rad GTPases. *Proc. Natl Acad. Sci.* **100**, 14469–14474 (2003).
41. Bannister, R. A., Colecraft, H. M. & Beam, K. G. Rem inhibits skeletal muscle EC coupling by reducing the number of functional L-type Ca<sup>2+</sup> channels. *Biophys. J.* **94**, 2631–2638 (2008).
42. Yang, T., Xu, X., Kernan, T., Wu, V. & Colecraft, H. M. Rem, a member of the RGK GTPases, inhibits recombinant Ca<sub>v</sub>1.2 channels using multiple mechanisms that require distinct conformations of the GTPases. *J. Physiol.* **588**, 1665–1681 (2010).
43. Altier, C. *et al.* The Cav $\beta$  subunit prevents RFP2-mediated ubiquitination and proteosomal degradation of L-type channels. *Nat. Neurosci.* **14**, 173–180 (2011).
44. Hou, T. *et al.* Characterization of domain-peptide interaction interface. *Mol. Cell. Proteomics* **8.4**, 639–649 (2009).
45. Shimoda, N. *et al.* Zebrafish genetic map with 2000 microsatellite markers. *Genomics* **58**, 219–232 (1999).
46. Callard, G. V. & McCurley, A. T. Characterization of housekeeping genes in zebrafish: male-female differences and effects of tissue type, developmental stage and chemical treatment. *BMC Mol. Biol.* **9**, 102 (2008).
47. Nesvizhskii, A. I., Keller, A., Kolker, E. & Aebersold, R. A statistical model for identifying proteins by tandem mass spectrometry. *Anal. Chem.* **75**, 4646–4658 (2003).
48. Rainier, S., Sher, C., Reish, O., Thomas, D. & Fink, J. K. *De novo* occurrence of a novel SPG3A/atlastin mutation presenting as cerebral palsy. *Arch. Neurol.* **63**, 445–447 (2006).
49. Dowling, J. J. *et al.* Loss of myotubularin function results in T-tubule disorganization in zebrafish and human myotubular myopathy. *PLoS. Genet.* **5**, e1000372 (2009).

## Acknowledgements

We thank Dr H. Xu (University of Michigan) for discussions of the experiments; B. Wagner, E. Andraska, M. Lacey and A. Migda for collecting and raising *stac3<sup>mi34</sup>* embryos; T. Waugh and T. Tubbs for assistance with human *STAC3* screening; Drs H. Okamoto (RIKEN, Japan) and L. Looger (Janelia Farms, HHMI) for plasmid constructs; Dr Hienriette Remmer (University of Michigan) for advise on mass spectrometry and data analysis; and the patients and families who provided biological samples. This research was supported by grants from NINDS (RO1NS54731) and NSF (0725976) to J.Y.K., NIAMS (1K08AR054835) and the Taubman Medical Institute to J.J.D., the Muscular Dystrophy Association (MDA186447) to M.A.H. and NIAMS (RO1HL048093) to C.F.-A. H.H. was supported by a Long-Term Fellowship and a Career Development Award from the Human Frontier Science Program, W.W.C. in part by a Center for Organogenesis Training Grant (NIH T32-HD007505), J.W.L. by the Cell and Molecular Biology Training Grant (NIH T32-GM-07315) and a Rackham Merit Fellowship from the University of Michigan.

## Author contributions

The zebrafish mutagenesis screen that isolated *stac3<sup>mi34</sup>* was performed by L.S.-A., W.W.C., W.Z., S.M.S., H.H. and J.Y.K. The behavioural analysis of *stac3<sup>mi34</sup>* was performed by H.H. and E.J.H. The electrophysiological and Ca<sup>2+</sup> imaging analysis of *stac3<sup>mi34</sup>* was performed by E.J.H. with some initial electrophysiological characterization by L.S.-A. Mutant rescue and NAM allele expression experiments were performed by E.J.H. Expression pattern of *Stac3* was delineated by E.J.H. and H.H. Generation of anti-*Stac3*, immunoblots, co-immunoprecipitations, demonstration of maternal *stac3* transcript and Morpholino knockdown of *Stac3* were performed by J.W.L. Meiotic mapping and molecular identification of *stac3<sup>mi34</sup>* was performed by H.H. Electron microscopy was performed by C.F.-A. and J.J.D. Human *STAC3* was cloned by A.S. NAM clinical phenotyping, original pedigree analysis and biological sample collection were performed

by C.M.P., D.S.S and M.C.S. Pedigree analysis of *STAC3* and Native American Myopathy was performed by J.J.D., K.K.M., A.A.-K. and M.A.H. The research was designed and the paper written by J.Y.K.

### Additional Information

**Supplementary Information** accompanies this paper at <http://www.nature.com/naturecommunications>

**Competing financial interests:** The authors declare no competing financial interests.

**Reprints and permission information** is available online at <http://npg.nature.com/reprintsandpermissions/>

**How to cite this article:** Horstick, E. J. *et al.* *Stac3* is a component of the excitation-contraction coupling machinery and mutated in Native American myopathy. *Nat. Commun.* 4:1952 doi: 10.1038/ncomms2952 (2013).